Half of US commercial health plans add coverage limits for gene and cell therapies beyond what they're approved for, ...

The development partners said they will share data with regulators, and AstraZeneca said it will harmonize its share listing across international stock exchanges.

The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.

The funding will support the firm's pipeline of mRNA and gene correction therapies, including an investigational inhaled mRNA therapy under testing for cystic fibrosis.

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

A real-world study showed that patients who had the classical subtype based on an RNA signature had better survival on ...

A team from Shriners Children's and Washington University in St. Louis are investigating a new method for personalizing ...

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.